A central mission of the IRIS Lab is to understand how cerebrovascular and brain structural changes relate to cognitive decline and Alzheimer's disease (AD) risk. The lab's work — conducted in collaboration with Wake Forest School of Medicine, UC Davis, and partners in the U.S. POINTER lifestyle intervention trial — examines how metrics such as cerebrovascular reactivity (CVR), cerebral blood flow, white matter integrity, and arterial stiffness differ between individuals with normal cognition and those with mild cognitive impairment (MCI).